187 related articles for article (PubMed ID: 19683429)
1. Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.
Pivot XB; Li RK; Thomas ES; Chung HC; Fein LE; Chan VF; Jassem J; de Mendoza FH; Mukhopadyay P; Roché HH
Eur J Cancer; 2009 Nov; 45(17):2940-6. PubMed ID: 19683429
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
3. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Yardley DA
Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
[TBL] [Abstract][Full Text] [Related]
4. Ixabepilone, a new treatment option for metastatic breast cancer.
Toppmeyer DL; Goodin S
Am J Clin Oncol; 2010 Oct; 33(5):516-21. PubMed ID: 20023567
[TBL] [Abstract][Full Text] [Related]
5. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Boehnke Michaud L
J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
[TBL] [Abstract][Full Text] [Related]
6. Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report.
Vrdoljak E; Mise BP; Lukić B; Curić Z; Bosković L; Tica I
Onkologie; 2010; 33(1-2):53-6. PubMed ID: 20164663
[TBL] [Abstract][Full Text] [Related]
7. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
[TBL] [Abstract][Full Text] [Related]
8. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
Vahdat L
Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
[TBL] [Abstract][Full Text] [Related]
9. Ixabepilone for the treatment of breast cancer.
Alvarez RH; Valero V; Hortobagyi GN
Ann Med; 2011; 43(6):477-86. PubMed ID: 21585248
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
Perez EA; Patel T; Moreno-Aspitia A
Breast Cancer Res Treat; 2010 Jun; 121(2):261-71. PubMed ID: 20229176
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA
Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
[TBL] [Abstract][Full Text] [Related]
12. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.
Chang HJ; Han SW; Oh DY; Im SA; Jeon YK; Park IA; Han W; Noh DY; Bang YJ; Kim TY
Jpn J Clin Oncol; 2011 May; 41(5):593-9. PubMed ID: 21406492
[TBL] [Abstract][Full Text] [Related]
13. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
16. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
17. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.
Baselga J; Zambetti M; Llombart-Cussac A; Manikhas G; Kubista E; Steger GG; Makhson A; Tjulandin S; Ludwig H; Verrill M; Ciruelos E; Egyhazi S; Xu LA; Zerba KE; Lee H; Clark E; Galbraith S
J Clin Oncol; 2009 Feb; 27(4):526-34. PubMed ID: 19075286
[TBL] [Abstract][Full Text] [Related]
18. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
20. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
